1 of 1
Story summary
- Hong Kong-listed mainland Chinese pharmaceutical firms are set to report profits in 2025.
- Tony Ren from Macquarie Capital asserts that 2025 will see performance of innovative drugs despite pricing pressures.
- Innovent Biologics becomes the first Chinese firm to sell a weight loss and diabetes drug.
- Innovent Biologics projects 984 million yuan profit in 2025.
- Innovent Biologics expects 45% revenue growth to 11.9 billion yuan in 2025.
